LLY · News · 20261103N
Revenue Performance and Mix
ELI LILLY & Co · 2026-11-03 · Importance 64 · Surprise 56 · No source text
Eli Lilly’s third-quarter 2026 revenue rose 39% year over year to $24.40 billion, while adjusted EPS increased 7% to $7.48. Volume grew 53%, more than offsetting a 15% decline in realized prices. Mounjaro and Zepbound were the primary growth engines, and newer medicines in oncology, immunology, and neuroscience also contributed to growth.
Key facts
- Q3 2026 revenue rose 39% year over year to $24.40 billion. source
- Lilly's Q3 2026 sales were US$24.4 billion and net income was US$6.5 billion. source
- Q3 2026 volume growth of 53% more than offset a 15% decline in realized prices. source
- Q3 2026 adjusted EPS rose 7% to $7.48. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +28.1% | Q3 2026 revenue rose 39% year over year to $24.40 billion. |
| revenue | positive | realized | — | Q3 2026 volume growth of 53% more than offset a 15% decline in realized prices. |
| revenue | negative | realized | — | Q3 2026 volume growth of 53% more than offset a 15% decline in realized prices. |